GLP-2R+ myofibroblasts in the small intestine and colon contain keratinocyte growth factor (KGF), whereby immunoneutralization of KGF abolishes the trophic effects of GLP-2 treatment in the colon, but not the small intestine in mice (Orskov et al., 2005)
Read review Dihexa for Huntingtons Disease AMT-130 gene therapy 75% slowing, WVE-003 allele-selective lowering, and the corticostriatal BDNF/TrkB axis
Results Enrollment and baseline demographics Herein we report results of a phase 1 clinical trial (www.clinicaltrials.gov, NCT02943239), involving a randomized, double-blind, placebo-controlled comparison assessing the safety, tolerability, pharmacokinetics, and pharmacodynamics of the GDF8 mAb, trevogrumab, and the ActA mAb, garetosmab, each given alone, as well as the GDF8 mAb given in combination with increasing dose levels of the ActA mAb
Researchers excluded participants who had other chronic liver problems besides nonalcoholic fatty liver disease